LOC390937_EG232974 Inhibitors
IFT122 Inhibitors primarily operate by blocking the signaling pathways that IFT122 is directly involved in. This can be achieved by inhibiting protein kinases like PKC and JNK, as well as Src-family kinases, all of which are known to activate IFT122. Specific inhibitors for these kinases include Staurosporine, Dasatinib, SP600125, Go6983, and Ro-31-8220. By inhibiting these kinases, these chemical compounds can lead to a decrease in the activation of IFT122. Furthermore, the NF-κB pathway is known to activate IFT122, therefore, inhibitors like BAY 11-7082 and BAY 11-7085 that reduces NF-κB activation can lead to decreased activation of IFT122.
Moreover, the MAPK pathway, specifically the MEK component, is known to activate IFT122. Therefore, MEK inhibitors like PD98059 and U0126 can decrease IFT122 activation. Additionally, the PI3K and mTOR signaling pathways are known to activate IFT122, soinhibitors such as LY294002 and Rapamycin, which block PI3K and mTOR respectively, can result in a decrease in IFT122 activation. Through these specific biochemical pathways, the activity of IFT122 can be inhibited directly or indirectly by the listed chemical compounds.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, as a protein kinase inhibitor, can potentially inhibit LOC390937_EG232974 by inhibiting protein kinases within the pathways associated with LOC390937_EG232974. This would lead to a decrease in the activation of LOC390937_EG232974. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a Src-family kinase inhibitor, can inhibit LOC390937_EG232974 by inhibiting Src-family kinases, which are known to activate LOC390937_EG232974. This results in decreased activation of LOC390937_EG232974. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, as a JNK inhibitor, can decrease the activation of LOC390937_EG232974 by inhibiting JNK, which is part of the signaling cascade that activates LOC390937_EG232974. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, as a PI3K inhibitor, can inhibit LOC390937_EG232974 by inhibiting PI3K, which is a known activator of LOC390937_EG232974. This leads to decreased activation of LOC390937_EG232974. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983, as a PKC inhibitor, can decrease the activation of LOC390937_EG232974 by inhibiting PKC, which is a known activator of LOC390937_EG232974. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, as an NF-κB inhibitor, can inhibit LOC390937_EG232974 by inhibiting NF-κB, a known activator of LOC390937_EG232974. This results in decreased activation of LOC390937_EG232974. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, as a MEK inhibitor, can decrease the activation of LOC390937_EG232974 by inhibiting MEK, which is part of the MAPK pathway that activates LOC390937_EG232974. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro-31-8220, as a PKC inhibitor, can inhibit LOC390937_EG232974 by inhibiting PKC, which is a known activator of LOC390937_EG232974. This leads to decreased activation of LOC390937_EG232974. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG 1478, as an EGFR tyrosine kinase inhibitor, can inhibit LOC390937_EG232974 by inhibiting EGFR, a known activator of LOC390937_EG232974. This results in decreased activation of LOC390937_EG232974. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
BAY 11-7085, as an NF-κB inhibitor, can inhibit LOC390937_EG232974 by inhibiting NF-κB, a known activator of LOC390937_EG232974. This results in decreased activation of LOC390937_EG232974. | ||||||